白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2011年
3期
165-167,171
,共4页
任涛%谭榜宪%柳弥%马代远%周业琴%舒晓红%周芨
任濤%譚榜憲%柳瀰%馬代遠%週業琴%舒曉紅%週芨
임도%담방헌%류미%마대원%주업금%서효홍%주급
鼻腔%淋巴瘤,NK/T细胞%预后%放射疗法
鼻腔%淋巴瘤,NK/T細胞%預後%放射療法
비강%림파류,NK/T세포%예후%방사요법
Nasal cavity%Lymphoma,NK/T-cell%Prognosis%Radiotherapy
目的 回顾分析鼻腔自然杀伤(NK)/T细胞淋巴瘤的放射治疗效果,并分析其预后因素.方法 回顾分析9年间接受放射治疗的62例鼻腔NK/T细胞淋巴瘤的临床资料和疗效,单因素分析采用Kaplan-Meier法,多因素分析用COX比例风险模型.结果 全组中位生存时间69.7个月(95%CI为63.0~78.0个月),3、5年总生存率分别为66.1%和46.8%,远处转移导致治疗失败占61.8%.T淋巴细胞CD3升高组和降低组的中位生存时间分别为72.6个月和39.6个月,两组比较差异有统计学意义(x2=4.9309,P=0.0264).多因素分析表明,修正后国际预后指数(IPI)为0~1(x2=7.5266,P=0.0061)、CD3升高(x2=9.0912,P=0.0266)和治疗结束达到CR(x2=9.0912,P=0.0106)是影响鼻腔NK/T细胞淋巴瘤放疗总生存的有利预后因素.结论 放射治疗鼻腔NK/T细胞淋巴瘤疗效肯定,但远处转移治疗失败率高,全身治疗仍具有重要地位;修正后IPI为0~1、CD3升高、治疗结束达到CR是影响鼻腔NK/T细胞淋巴瘤放疗总生存的有利预后因素.
目的 迴顧分析鼻腔自然殺傷(NK)/T細胞淋巴瘤的放射治療效果,併分析其預後因素.方法 迴顧分析9年間接受放射治療的62例鼻腔NK/T細胞淋巴瘤的臨床資料和療效,單因素分析採用Kaplan-Meier法,多因素分析用COX比例風險模型.結果 全組中位生存時間69.7箇月(95%CI為63.0~78.0箇月),3、5年總生存率分彆為66.1%和46.8%,遠處轉移導緻治療失敗佔61.8%.T淋巴細胞CD3升高組和降低組的中位生存時間分彆為72.6箇月和39.6箇月,兩組比較差異有統計學意義(x2=4.9309,P=0.0264).多因素分析錶明,脩正後國際預後指數(IPI)為0~1(x2=7.5266,P=0.0061)、CD3升高(x2=9.0912,P=0.0266)和治療結束達到CR(x2=9.0912,P=0.0106)是影響鼻腔NK/T細胞淋巴瘤放療總生存的有利預後因素.結論 放射治療鼻腔NK/T細胞淋巴瘤療效肯定,但遠處轉移治療失敗率高,全身治療仍具有重要地位;脩正後IPI為0~1、CD3升高、治療結束達到CR是影響鼻腔NK/T細胞淋巴瘤放療總生存的有利預後因素.
목적 회고분석비강자연살상(NK)/T세포림파류적방사치료효과,병분석기예후인소.방법 회고분석9년간접수방사치료적62례비강NK/T세포림파류적림상자료화료효,단인소분석채용Kaplan-Meier법,다인소분석용COX비례풍험모형.결과 전조중위생존시간69.7개월(95%CI위63.0~78.0개월),3、5년총생존솔분별위66.1%화46.8%,원처전이도치치료실패점61.8%.T림파세포CD3승고조화강저조적중위생존시간분별위72.6개월화39.6개월,량조비교차이유통계학의의(x2=4.9309,P=0.0264).다인소분석표명,수정후국제예후지수(IPI)위0~1(x2=7.5266,P=0.0061)、CD3승고(x2=9.0912,P=0.0266)화치료결속체도CR(x2=9.0912,P=0.0106)시영향비강NK/T세포림파류방료총생존적유리예후인소.결론 방사치료비강NK/T세포림파류료효긍정,단원처전이치료실패솔고,전신치료잉구유중요지위;수정후IPI위0~1、CD3승고、치료결속체도CR시영향비강NK/T세포림파류방료총생존적유리예후인소.
Objective To retrospectively analyze the efficacy of radiotherapy on nasal NK/T-cell lymphoma, and to explore the prognostic factors. Methods Between January 2000 and December 2008, 62 patients with nasal NK/T-cell lymphoma were treated with radiotherapy in our hospital. Their clinic data and efficiency were reviewed retrospectively. Kaplan-Meier methods were applied in unifactorial analysis and the COX regression model was applied in multivariate analysis. Results The median overall survival time was 69.7 months (95 % CI, 63.0-78.0 months), and 3, 5-year survival rate was 66.1% and 46.8 %. Metastasis was 61.8 % for the first reason which resulted in failure. The median survival time was 72.6 months in the increased group of numbers of T lymphocyte CD3 and 39.6 months in the decreased group, the difference was significant(x2 =4.9309, P =0.0264). Multivariate analysis confirmed that modified IPI 0-1 (x2 = 7.5266, P =0.0061), the numbers increased for CD3 (x2 =9.0912, P =0.0266), and complete remission(x2 = 9.0912, P =0.0106) were significant favorable prognostic factors for survival. Conclusion The radiotherapy was effective for patients with nasal NK/T-cell lymphoma, but was failure on account of distant metastasis, so systematic therapy still has an important role. modified IP1 0-1, the number increased for CD3 and complete remission were significant favorable prognostic factors for survival.